Table 2 Demographic and baseline characteristics for all randomized patients who entered the 12-week treatment period
Demographic variable | All patients | |
|---|---|---|
Age, years (n = 93) | ||
Mean ± SD | 21.6 ± 7.7 | |
Median (min, max) | 21.0 (9, 42) | |
≥18 years of age, n (%) | 58 (62.4) | |
Male, n (%) (n = 93) | 64 (68.8) | |
White, n (%) (n = 93) | 88 (94.6) | |
Height, cm (n = 93) | ||
Mean ± SD | 172.3 ± 11.5 | |
Median (min, max) | 174.1 (134.1, 195.6) | |
Weight, kg (n = 93) | ||
Mean ± SD | 70.1 ± 17.1 | |
Median (min, max) | (69.8, 117.1) | |
Time since diagnosis of EoE, monthsa (n = 87) | ||
Mean ± SD | 37.6 ± 38.2 | |
Median (min, max) | 26.3 (−0.1, 164.2) | |
Physician Global Assessment of disease activity (n = 93) | ||
Mean ± SD | 58.3 ± 21.5 | |
Median (min, max) | 62.0 (0, 94.0) | |
DSQ score (n = 92) | ||
Mean ± SD | 29.8 ± 14.8 | |
Median (min, max) | 28.0 (6.5, 61.1) | |
Peak eosinophil count (eos/hpf) | Placebo (n = 42) | BOS (n = 51) |
Mean ± SD | 133.0 ± 81.6 | 157.8 ± 96.1 |